Published in Int J Neuropsychopharmacol on March 28, 2015
Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder. Curr Pharm Des (2015) 0.79
Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodev Disord (2017) 0.79
Effects of acute administration of the GABA(B) receptor agonist baclofen on behavioral flexibility in rats. Psychopharmacology (Berl) (2016) 0.78
FMRP regulates an ethanol-dependent shift in GABABR function and expression with rapid antidepressant properties. Nat Commun (2016) 0.76
GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the Fmr1 Knockout Mouse Model of Fragile X Syndrome. eNeuro (2017) 0.75
Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial. Neuropsychopharmacology (2016) 0.75
Behavioral Phenotype of Fmr1 Knock-Out Mice during Active Phase in an Altered Light/Dark Cycle. eNeuro (2016) 0.75
Effects of a social stimulus on gene expression in a mouse model of fragile X syndrome. Mol Autism (2017) 0.75
Developmental Disruption of GABAAR-Meditated Inhibition in Cntnap2 KO Mice. eNeuro (2017) 0.75
Deficient Sleep in Mouse Models of Fragile X Syndrome. Front Mol Neurosci (2017) 0.75
The mGluR theory of fragile X mental retardation. Trends Neurosci (2004) 8.88
FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell (2011) 8.46
Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A (2002) 6.45
Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron (2012) 4.31
Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci (2010) 3.73
G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron (1997) 3.52
Advances in the treatment of fragile X syndrome. Pediatrics (2009) 3.10
Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron (2006) 2.53
Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med (2012) 2.51
Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci (2010) 2.42
Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J Neurosci (2005) 2.40
The growing role of mTOR in neuronal development and plasticity. Mol Neurobiol (2006) 2.22
(Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet (2000) 2.17
Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med (2012) 1.72
The GABAA receptor: a novel target for treatment of fragile X? Trends Neurosci (2007) 1.54
Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron (2012) 1.52
Stain-Free technology as a normalization tool in Western blot analysis. Anal Biochem (2012) 1.50
A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. J Neurosci (2005) 1.47
GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS One (2010) 1.47
Translating glutamate: from pathophysiology to treatment. Sci Transl Med (2011) 1.42
Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol (2010) 1.31
A fragile balance: FMR1 expression levels. Hum Mol Genet (2003) 1.27
Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A (2002) 1.25
Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome. Neurosci Lett (2009) 1.22
Measurement of local cerebral protein synthesis in vivo: influence of recycling of amino acids derived from protein degradation. Proc Natl Acad Sci U S A (1988) 1.18
GABA(B)-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons. Neuron (1997) 1.17
A null mutation for Fmr1 in female mice: effects on regional cerebral metabolic rate for glucose and relationship to behavior. Neuroscience (2005) 1.15
Subchronic administration and combination metabotropic glutamate and GABAB receptor drug therapy in fragile X syndrome. J Pharmacol Exp Ther (2011) 0.96
Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome. Neurobiol Dis (2011) 0.94
Brief report: altered social behavior in isolation-reared Fmr1 knockout mice. J Autism Dev Disord (2013) 0.80